Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Biological Therapy Ilaris(R) Approved In US To Treat Children And Adults With CAPS, A Serious Life-Long Auto-Inflammatory Disease
The U.S. Food and Drug Administration (FDA) has approved Ilaris(R) (canakinumab) for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), which includes a number of rare, but life-long, auto-inflammatory disorders with debilitating symptoms and limited treatment options. The FDA granted priority review to Ilaris based on its potential to meet an important clinical need for patients with CAPS.
generic viagra online
Swine Flu: Health Departments Get Mixed Marks For Using Web To Communicate About Crisis, Study Finds
State and local health departments get mixed marks for efforts to convey information about the H1N1 virus to the public using their Web sites immediately after U.S. officials declared a public health emergency in April, according to a new RAND Corporation study.
News of the day
START Trial Will Show Whether Therapeutic Vaccine Stimuvax Has Potential To Extend Lung Cancer Survival Beyond Five Years
Of all cancers, non-small cell lung cancer (NSCLC) represents one of the greatest unmet needs for an effective and life-prolonging treatment. The condition, which accounts for 85 per cent of all lung cancers - roughly 1.4 million worldwide each year - is rarely diagnosed at its earliest and most potentially curable stage when it is amenable to surgical resection. Most patients are diagnosed when the tumour has already advanced to stage III, where it has invaded the chest tissues or mediastinal lymph nodes and is inoperable, or to stage IV where it has spread to other organ sites. Around 30 per cent are diagnosed at stage III and 40 per cent at stage IV. Both stages carry a poor prognosis. From stage III, and following chemo and radiotherapy treatment, median survival has been at best only between 13 and 18 months.
Sexual Health

Changing The EU Public Health Dynamic: Better Science, Regulation And Access Policies To Deliver Biopharmaceutical Innovation For Europe's Citizens

Better science, better regulation and better access policies are needed in Europe to support an innovative healthcare industry and the bio-pharmaceutical industry to deliver state-of-the-art standards of prevention, treatment and cures for EU citizens. This was today the plea to policy-makers by EuropaBio which organised a major event at the BIO Convention in Atlanta. During the session entitled Europe: The Changing Dynamics of the Public Health Environment Thomas Lonngren, Executive Director at the European Medicines Agency (EMEA), Giulia Del Brenna, Head of Unit, competitiveness in the pharmaceuticals industry and biotechnology at the European Commission, Directorate General Enterprise and Industry, and Francois Meyer, Head of HTA at Haute Authorite de Sante (HAS) and member of the EUnetHTA network, discussed ways to improve the EU decision making process to allow direct involvement, for stakeholders, increased public consultation and more co-decision between institutional actors. EuropaBio reiterated its call for further and better regulation, involving all EU stakeholder groups, to ensure that patients are at the centre of public health policies to effectively answer society"s unmet healthcare needs. "In the weeks to come, the EU will welcome a new European Parliament and a new European Commission. We are calling on them to ensure that there will be even stronger dialogue between policy-makers, regulators, HTA bodies and relevant stakeholders to ensure that patients" interests are at the heart of every healthcare policy and legislation in Europe," says Andrea Rappagliosi, Chair of the Healthcare Council at EuropaBio. He added: "To secure timely and equal public access to safe, high quality and efficient bio-pharmaceutical products, we urge the setting up of coordinated political and regulatory measures in healthcare, from prevention to treatment. This will ensure that patients and citizens receive the most innovative healthcare solutions available, and that payers secure value for the investments they make." Following the success of its session at the BIO Convention and guided by the principles of its Healthcare Manifesto (1), EuropaBio will continue to work hand-in-hand with EU policy-makers, regulators, patients" advocacy groups and all healthcare stakeholders to ensure that EU healthcare systems in Europe are patient-centred. (1) EuropaBio"s Healthcare Manifesto 2009-2010 EuropaBio"s Healthcare Manifesto is the Healthcare Council"s Political Road Map for 2009 and 2010 for how to deliver a patient-centred approach to modern healthcare. The Healthcare Manifesto is available here. EuropaBio


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009